PUBLICATION AND RESOURCES

PUBLICATIONS

10.28.2020 | JCO Precision Oncology
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer

Andrew J. Armstrong, MD, ScM1; Jun Luo, PhD2; David M. Nanus, MD3; Paraskevi Giannakakou, PhD3; Russell Z. Szmulewitz, MD4; Daniel C. Danila, MD3,5; Patrick Healy, MS; Monika Anand, PhD1; William R. Berry, MD1; Tian Zhang, MD1; Michael R. Harrison, MD1; Changxue Lu, MM, PhD2; Yan Chen, BM, PhD2; Giuseppe Galletti, MD, PhD3; Joseph D. Schonhoft, PhD7; Howard I. Scher, MD5; Richard Wenstrup, MD7; Scott T. Tagawa, MD3; Emmanuel S. Antonarakis, MD2,8; Daniel J. George, MD1; and Susan Halabi, PhD8
7.1.2020 | Clinical Cancer Research
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JM, Sboner A, Nanus DM, Elemento O, Dittamore R, Tagawa ST, Beltran H.Mol Cancer Ther. 2020 May;19(5):1157-1164. DOI: 10.1158/1535-7163
7.1.2020 | Clinical Cancer Research
Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer

Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ.Clin Cancer Res. 2020 Apr 27. DOI: 10.1158/1078-0432.CCR-19-4100
5.30.2019 | JCO Precision Oncology
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer

Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their clinical implication.
FULL PUBLICATION LIST

Resources

SCIENTIFIC POSTERS

2.11.2021
Development and Validation of Circulating Tumor Cell Enumeration (Epic Sciences) as a Prognostic Biomarker in Men with Metastatic Castration Resistant Prostate Cancer.
2.11.2021
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
12.18.2020
Pilot Trial of Priming With Oral TAK-228 and TAK-117 (PIKTOR) to Increase DNA Damage Repair Deficiency Followed By Cisplatin and Nab Paclitaxel in Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer Patients.
10.22.2020
Circulating Tumor Cells (CTCs) With Small-Cell Like Features are Prevalent in Metastatic Castration Resistant Prostate Cancer (mCRPC) and Show Selective Pharmacodynamic Reductions in Patients Treated With Platinum Therapy but not an ARSi or Taxane.
All SCIENTIFIC POSTERS

PACKAGE INSERTS

AR-V7 Blood Collection Kit Package Insert (Kit FM-00049 and FM-00076)
CE Mark Blood Collection Kit Package Insert (Kit FM-000107)
CTC Liquid Biopsy Blood Collection Kit Requisition Form (LBL-00081)
ALL INSERTS

EPIC PODCAST: FEATURED

6.13.2019
EPISODE 02 | LAUREN LEIMAN

In Episode 2 of Innovations in Cancer, we speak with Lauren Leiman, executive director at BloodPAC, the Blood Profiling Atlas in Cancer (BloodPAC) Consortium, launched October 2017, to accelerate the development and validation of liquid biopsy assays to improve the outcomes of patients with cancer. Lauren discusses the collaborative infrastructure that enables sharing of information between stakeholders in industry, academia, and regulatory agencies with the goal to standardize liquid biopsies to improve outcomes for patients.

Listen Now
MORE EPISODES